Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an anti-apoptotic gene, comprising a complementary RNA strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially identical to at least a part of an apoptotic gene, such as a Bcl gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition; and methods for inhibiting the expression of an anti-apoptotic gene in a cell.
Type:
Grant
Filed:
March 7, 2003
Date of Patent:
January 6, 2009
Assignee:
Alnylam Europe AG
Inventors:
Roland Kreutzer, Stefan Limmer, Hans-Peter Vornlocher, Philipp Hadwiger, Anke Geick, Matthias Ocker, Christoph Herold, Detlef Schuppan
Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3?-untranslated region (3?-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.
Type:
Grant
Filed:
March 7, 2003
Date of Patent:
March 25, 2008
Assignee:
Alnylam Europe AG
Inventors:
Matthias John, Stefan Limmer, Hans-Peter Vornlocher, Roland Kreutzer
Abstract: The present invention relates to the specific inhibition of expression of a fusion gene in mammals using a short double stranded RNA. The dsRNA is approximately 19–24 nucleotides in length, and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases caused by chromosomal aberrations, particularly malignant diseases such as lymphoma and leukemia.
Type:
Grant
Filed:
January 22, 2003
Date of Patent:
March 27, 2007
Assignee:
Alnylam Europe AG
Inventors:
Olaf Heidenreich, Hans-Peter Vornlocher, Roland Kreutzer, Stefan Limmer